Home › Compare › SCWTF vs ABBV
SCWTF yields 5.70% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SCWTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SCWTF + ABBV for your $10,000?
Schweiter Technologies AG engages in the development, production, and distribution of extruded and cast plastic sheets, composite panels, and core materials for composite structures in Europe, the Americas, Asia, and internationally. The company offers new generation for traffic signs made from aluminum composite panels; decorative façade material and innovative roof cladding made from aluminum composite panels; individual photo wall, printed on lightweight foam sheets; and cycle shelter with optimum weather protection from extruded acrylic sheets. It also provides lightweight composite elements for buses and coaches; lightweight chassis for city buses; high-quality baths and basins from thermoformed acrylic sheets; mats and balance pads for the fitness/sports and physio market; PET rigid foams for wind farm components; structural balsa wood for wind farm components; and greenhouse made of virtually unbreakable extruded multiwall polycarbonate sheets. The company serves the display, architecture, wind energy, marine, transportation, and industrial markets. It offers its products under the AIREX, ALUCOBOND, BALTEK, DIBOND, FOREX, GATOR, KAPA, PERSPEX, SINTRA, CRYLON, and CRYLUX brands. In addition, it is involved in the property management and management activities. The company was founded in 1912 and is headquartered in Steinhausen, Switzerland.
Full SCWTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.